2-甲基-4-三甲基硅乙炔基噻唑 | 329203-85-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-甲基-4-三甲基硅乙炔基噻唑
• 英文名称: 2-methyl-4-((trimethylsilyl)ethynyl)thiazole
• 英文别名: 4-(trimethylsilylethynyl)-2-methyl-1,3-thiazole；2-methyl-4-[(trimethylsilyl)ethynyl]-1,3-thiazole；2-Methyl-4-[2-(trimethylsilyl)ethynyl]-1,3-thiazole；trimethyl-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]silane
• CAS: 329203-85-2
• 化学式: C₉H₁₃NSSi
• mdl: MFCD09031635
• 分子量: 195.36
• InChiKey: UKKNFAGXYOWTDR-UHFFFAOYSA-N

物化性质

• 沸点：
  231℃
• 密度：
  1.02
• 闪点：
  93℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.08
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  2-甲基-4-三甲基硅乙炔基噻唑 在 四丁基氟化铵 氢氧化钾 、 copper(l) iodide 、 四(三苯基膦)钯 、 氢溴酸 、 溶剂黄146 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.75h， 生成 2-chloro-5-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine Analogues as Potent, Noncompetitive Metabotropic Glutamate Receptor Subtype 5 Antagonists; Search for Cocaine Medications

  摘要：

  Recent genetic and pharmacological studies have suggested that the metabotropic glutamate receptor subtype 5 (mGluR5) may represent a druggable target in identifying new therapeutics for the treatment of various central nervous system disorders including drug abuse. In particular, considerable attention in the mGluR5 field has been devoted to identifying ligands that bind to the allosteric modulatory site, distinct from the site for the primary agonist glutamate. Both 2-methyl-6-(phenylethynyl)pyridine (MPEP) and its analogue 3-[(2-methyl-4-thiazolyl)ethynyl]pyridine (MTEP) have been shown to be selective and potent noncompetitive antagonists of mGluR5. Because of results presented in this study showing that MTEP prevents the reinstatement of cocaine self-administration caused by the presentation of environmental cues previously associated with cocaine availability, we have prepared a series of analogues of MTEP with the aim of gaining a better understanding of the structural features relevant to its antagonist potency and with the ultimate aim of investigating the effects of such compounds in blunting the self-administration of cocaine. These efforts have led to the identification of compounds showing higher potency as mGluR5 antagonists than either MPEP or MTEP. Two compounds 19 and 59 exhibited functional activity as mGluR5 antagonists that are 490 and 230 times, respectively, better than that of MTEP.

  DOI：

  10.1021/jm050570f
• 作为产物：
  描述：

  二(三甲基甲硅烷基)乙炔 在 aluminum (III) chloride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 2-甲基-4-三甲基硅乙炔基噻唑
  参考文献：
  名称：

  Enhanced copper-mediated ¹⁸F-fluorination of aryl boronic esters provides eight radiotracers for PET applications

  摘要：

  使用铜介导的非载体添加亲核性¹⁸F-氟化技术，从芳基硼酸酯前体中分离出了八种临床相关的放射性示踪剂。

  DOI：

  10.1039/c6cc03295h

文献信息

• NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS
  申请人：Leonardi Amedeo

  公开号：US20090042841A1

  公开（公告）日：2009-02-12

  This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).

  本发明涉及一种新型杂环化合物，其具有选择性亲和力，适用于代谢型受体mGlu5亚型，以及该类化合物的制药组合物及其在治疗下尿路障碍（例如下尿路神经肌肉功能障碍）、偏头痛和胃食管反流病（GERD）方面的用途。
• Alkyne derivatives as tracers for metabotropic glutamate receptor binding
  申请人：Cosford Peter Nicholas David

  公开号：US20070060618A1

  公开（公告）日：2007-03-15

  The present invention is directed to isotopically labeled alkyne derivative compounds, particularly 11 C, 13 C, 14 C, 18 F, 15 O, 13 N, 35 S, 2 H, and 3 H labeled compounds. In particular, the present invention is directed to 11 C, 13 C, 14 C, 18 F, 15 O, 13 N, 35 S, 2 H, and 3 H labeled heterocyclic alkynes and methods of their preparation. The present invention further includes a method of use of the 11 C, 18 F, 15 O, or 13 N labeled heterocyclic alkyne compounds as tracers in positron emission tomography (PET) imaging, particularly in the study of metabolic conditions in mammals, specifically conditions modulated by metabotropic glutamate receptors subtype 5 (mGluR5).

  本发明涉及同位素标记的炔基衍生物化合物，特别是11C、13C、14C、18F、15O、13N、35S、2H和3H标记的化合物。具体而言，本发明涉及11C、13C、14C、18F、15O、13N、35S、2H和3H标记的杂环炔烃及其制备方法。本发明还包括将11C、18F、15O或13N标记的杂环炔烃化合物用作正电子发射断层扫描（PET）成像中的示踪剂的使用方法，特别是在哺乳动物代谢状况的研究中，特别是通过代谢型谷氨酸受体亚型5（mGluR5）调节的状况。
• Synthesis toward Bivalent Ligands for the Dopamine D₂ and Metabotropic Glutamate 5 Receptors
  作者：Mingcheng Qian、Elise Wouters、James A. R. Dalton、Martijn D. P. Risseeuw、René A. J. Crans、Christophe Stove、Jesús Giraldo、Kathleen Van Craenenbroeck、Serge Van Calenbergh

  DOI：10.1021/acs.jmedchem.8b00671

  日期：2018.9.27

  In this study, we designed and synthesized heterobivalent ligands targeting heteromers consisting of the metabotropic glutamate 5 receptor (mGluR5) and the dopamine D2 receptor (D2R). Bivalent ligand 22a with a linker consisting of 20 atoms showed 4-fold increase in affinity for cells coexpressing D2R and mGluR5 compared to cells solely expressing D2R. Likewise, the affinity of 22a for mGluR5 increased

  在这项研究中，我们设计和合成了针对由代谢型谷氨酸5受体（mGluR5）和多巴胺D 2受体（D 2 R）组成的异聚体的异二价配体。二价配体22A用由20个原子的连接体显示出对细胞共表达d亲和力增加4倍2 R和mGluR5的细胞相比表达单独d 2 R.同样地，所述亲和22A用于治疗mGluR5在共表达细胞中增加2倍。此外，在共表达D 2 R和mGluR5的细胞中，22a的mGluR5亲和力比其单价前体21a高5倍。这些结果表明22a能够桥接构成异二聚体的两个受体上的结合位点。同样，cAMP分析显示22a在稳定的D 2 R和mGluR5共表达细胞系中的效能比1高4倍。此外，分子建模揭示了22a能够通过在TM5-TM6界面之间通过并建立6个蛋白质-配体H键而同时结合两个受体。
• [EN] NOVEL GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] NOUVEL INHIBITEUR GALACTOSIDE DE GALECTINES
  申请人：GALECTO BIOTECH AB

  公开号：WO2021004940A1

  公开（公告）日：2021-01-14

  The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-1 and/or 3 inhibitors for use in treatment of inflammation; Inflammation induced thrombosis; Atopic dermatitis; Acute coronary syndrome; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart; local fibrosis such as Dupuytren's disease and Peyronie's disease; fibrotic complications of other therapies such as coronary stents, bile duct stents, cerebral artery stents, ureter stents; scleroderma; scarring; keloid formation; covid-19; acute lung injury; ARDS; viral pneumonitis, aberrant scar formation; surgical adhesions; septic shock; cancer, such as colorectal cancer, other gastrointestinal carcinomas such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancers, mesothelioma, female cancers like breast cancer, ovarian cancer, uterine cancer, cancer of the cervix uteri, cancer of the salpingx, cerebral cancers such as medulloblastomao, glioma, meningioma, sarcomas of the bones and muscles and other sarcomas, leukemias and lymphomas, such as T-cell lymphomas; transplant rejection; metastasising cancers; ageing; Dementia; Alzheimers; TGFbeta driven bone disease such as osteogenesis imperfecta; Pulmonary hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Rheumatoid lung; Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, Herpes virus, Coronaviruses, Hepatitis C; metabolic disorders; heart disease; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistens; obesity; Marfans syndrome; Loeys–Dietz syndrome; nephropathy; Diastolic HF; fibrotic lung complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, liver disorders, such as non- alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine disease such as uterine fibroids and uterine or cervical fibrosis.

  本发明涉及一种化学式（1）中的D-半乳糖吡喃糖类化合物，其中吡喃糖环为β-D-半乳糖吡喃糖，并且这些化合物是高亲和力的galectin-1和/或3抑制剂，用于治疗炎症；炎症诱导性血栓形成；特应性皮炎；急性冠状动脉综合征；纤维化，如肺纤维化、肝纤维化、肾脏纤维化、眼科纤维化和皮肤和心脏的纤维化；局部纤维化，如杜普伊特伦氏病和佩龙氏病；其他治疗的纤维化并发症，如冠状支架、胆管支架、脑动脉支架、输尿管支架；硬皮病；瘢痕形成；瘢痕增生；新冠肺炎；急性肺损伤；ARDS；病毒性肺炎；异常瘢痕形成；手术粘连；脓毒性休克；癌症，如结直肠癌、其他胃肠癌，如胰腺癌、胃癌、胆道癌、肺癌、间皮瘤、女性癌症如乳腺癌、卵巢癌、子宫癌、宫颈癌、输卵管癌、脑癌如髓母细胞瘤、胶质瘤、脑膜瘤、骨骼和肌肉的肉瘤和其他肉瘤、白血病和淋巴瘤，如T细胞淋巴瘤；移植排斥；转移性癌症；衰老；痴呆症；阿尔茨海默病；TGFbeta驱动的骨疾病，如骨发育不全；肺动脉高压；自身免疫疾病，如牛皮癣、类风湿关节炎、类风湿肺；克罗恩病、溃疡性结肠炎、强直性脊柱炎、系统性红斑狼疮；病毒感染，如流感病毒、HIV、疱疹病毒、冠状病毒、丙型肝炎；代谢紊乱；心脏病；心力衰竭；病理性血管生成，如眼部血管生成或与眼部血管生成相关的疾病或症状，例如与癌症相关的新血管生成；眼部疾病，如老年性黄斑变性和角膜新血管生成；动脉粥样硬化；代谢性疾病；糖尿病；1型糖尿病；2型糖尿病；胰岛素抵抗；肥胖；马凡氏综合征；洛伊斯-迪茨综合征；肾病；舒张期心力衰竭；aPD1和其他CPI疗法的肺纤维化并发症；哮喘和其他间质性肺疾病，包括赫尔曼斯基-普德拉克综合征、肝脏疾病，如非酒精性脂肪性肝炎或非酒精性脂肪肝病；子宫疾病，如子宫肌瘤和子宫或宫颈纤维化。
• Catalysis by zeolite leading to the construction of thiazole ring: an improved synthesis of 4-alkynyl substituted thiazoles
  作者：K. Arunkumar、D. Naresh Kumar Reddy、K.B. Chandrasekhar、P. Rajender Kumar、K. Shiva Kumar、Manojit Pal

  DOI：10.1016/j.tetlet.2012.05.062

  日期：2012.7

  facilitated the reaction of α-chloro acetyl chloride with 1,2-bis-trimethyl silyl acetylene to give 1-chloro-4-(trimethylsilyl)but-3-yn-2-one which on treatment with thioacetamide afforded 2-methyl-4-[(trimethylsilyl)ethynyl]thiazole. l-Proline on the other hand facilitated the coupling reaction of 2-methyl-4-[(trimethylsilyl)ethynyl]thiazole with (hetero)aryl halides (modified Sonogashira reaction) under Pd-Cu

  H-β沸石促进α-氯代乙酰氯与1,2-双-三甲基甲硅烷基乙炔的反应，生成1-氯-4-（三甲基甲硅烷基）but-3-yn-2-one，经硫代乙酰胺处理后得到2 -甲基-4-[（三甲基甲硅烷基）乙炔基]噻唑。另一方面，1-脯氨酸在K 2 CO 3水溶液存在下，在Pd-Cu催化下促进了2-甲基-4-[（三甲基甲硅烷基）乙炔基]噻唑与（杂）芳基卤化物的偶联反应（改良的Sonogashira反应）。提供了一种用于合成相应的4-炔基取代的噻唑衍生物的改进方法。